Prognostic molecular markers specific for squamous and adenocarcinoma of the cervix and uses thereof
By using adenosine kinase 4 and spongiform malformation 2 protein as prognostic markers for cervical cancer, the problem of lacking specificity in assessing the prognosis of squamous cell carcinoma and adenocarcinoma of the cervical cancer in existing technologies has been solved, enabling more precise diagnosis and treatment, and improving the survival rate and quality of life of cervical cancer patients.
Patent Information
- Application Number
- CN202510654310.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-21
- Publication Date
- 2026-04-10
- Estimated Expiration
- 2045-05-21
AI Technical Summary
The lack of biomarkers in current technologies that can specifically assess the prognosis of squamous cell carcinoma and adenocarcinoma of the cervix leads to poor diagnostic and treatment outcomes, especially since adenocarcinoma progresses rapidly and has low sensitivity to chemotherapy, resulting in poor patient prognosis.
Adenosine kinase 4 and spongiform malformation 2 protein were used as prognostic biomarkers for cervical squamous cell carcinoma and adenocarcinoma. The levels of these biomarkers were detected by methods such as ELISA, immunofluorescence analysis, and PCR. Corresponding kits or detection devices were designed to achieve accurate diagnosis and personalized treatment.
It provides novel biomarkers that can be used to assess the prognosis of cervical cancer, improving the specificity and accuracy of diagnosis, supporting the development of personalized treatment plans, and improving patient outcomes.